Thu, May 1, 8:06 PM (17 days ago)
**Moderna, Inc. (MRNA) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** Total revenue was $108M, down 35% from $167M in Q1 2024. Net product sales were $86M, a 49% decrease from $167M in Q1 2024, primarily due to lower COVID-19 vaccine sales. - **Profit Margins:** Operating loss was $1,050M, a 17% improvement from $1,266M in Q1 2024. Net loss was $971M, a 17% improvement from $1,175M in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $1,037M, a 5% increase from $989M in Q1 2024. Net cash provided by investing activities was $730M, a 519% increase from $118M in Q1 2024. - **Earnings Changes:** Net loss per share was $2.52, a 18% improvement from $3.07 in Q1 2024. **Trends & Uncertainties:** - **Seasonal Demand:** COVID-19 and RSV vaccine sales are expected to follow a seasonal pattern, with higher sales in fall and winter. - **Market Competition:** Increased competition and lower vaccination rates are expected to impact future sales. - **Pipeline Progress:** Moderna continues to advance its pipeline, with several programs in clinical trials. - **Legal Proceedings:** Moderna is involved in several patent litigation cases, which may impact future operations. **Future Operations Impact:** - **Cost Management:** Moderna is focusing on cost efficiency and disciplined cost management. - **Investment:** Continued investment in research and development, manufacturing capabilities, and global commercial infrastructure. - **Funding:** Moderna believes its current financial resources will be sufficient to support operations through at least the next 12 months. **Key Metrics:** - **Cash & Investments:** $8,393M as of March 31, 2025, down 12% from December 31, 2024. - **Working Capital:** $5,162M as of March 31, 2025, down 12% from December 31, 2024. - **Deferred Revenue:** $154M as of March 31, 2025, with $96M expected to be realized in less than one year. **Conclusion:** Moderna's Q1 2025 results reflect the ongoing transition of the COVID-19 vaccine market to a seasonal pattern, with lower sales and increased competition. The company is focusing on cost management, pipeline advancement, and strategic investments to support future growth. However, uncertainties related to market demand, competition, and legal proceedings may impact future operations.